TRECONDYV DIN 02517388
Health Canada record
| Active ingredient(s) | TREOSULFAN 5 G |
|---|---|
| Dosage form | Powder |
| Route | Intravenous |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L01AB02 TREOSULFAN |
| Original market date | 31-Aug-2021 |
| Current status date | 31-Aug-2021 |
| Source | Health Canada DPD |
Establishment licence of the holder
Medexus Pharmaceuticals Inc. — licence 101526, currently licensed, last inspection rating C (2026-02-19).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TREOSULFAN
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02517361 | TRECONDYV | MEDEXUS PHARMACEUTICALS INC. | Powder | TREOSULFAN 1 G | Approved |
| 02560585 | TREOSULFAN FOR INJECTION | MARCAN PHARMACEUTICALS INC | Powder | TREOSULFAN 5 G | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 26154 | 2021-06-25 | New Drug Submission (NDS) |
International API supply for TREOSULFAN
2 active FDA Drug Master Files.
Request a quote for TRECONDYV